Director of Regulatory Affairs

A Director of Regulatory Affairs is the primary expert on how FDA, EMA, and other health authorities will evaluate a company's products and programs. When the clinical team wants to design a Phase III trial, the regulatory director assesses whether the proposed endpoints are acceptable to FDA. When manufacturing wants to change an API supplier, the regulatory director evaluates whether that change requires a prior approval supplement or a CBE-30. When the CMO asks whether accelerated approval is achievable for a particular indication, the regulatory director provides the strategic assessment.

Submission management is the most visible deliverable. An NDA or BLA is a massive, structured document — 20 to 100+ modules in the electronic Common Technical Document (eCTD) format — that summarizes the entire preclinical and clinical evidence package for an investigational product. The Director oversees the preparation of this document: commissioning each section, coordinating with clinical science and biostatistics on data summaries, managing the production and quality review process, and ensuring the submission meets FDA's technical requirements. A submission that fails to meet technical standards is rejected before it's reviewed for content.

Agency meetings require strategic preparation that goes beyond document writing. A Type B end-of-Phase II meeting is an opportunity to get FDA alignment on the pivotal trial design before executing it. The Director prepares a briefing document that presents the efficacy and safety data to date, the proposed Phase III design, and specific questions for FDA comment. How those questions are framed — and whether the Director knows which questions to ask — materially affects whether the meeting produces actionable guidance or ambiguous discussion that leaves the company uncertain about the path forward.

Education:

• PhD in pharmacology, chemistry, biology, or a related science preferred
• PharmD or MD for roles with clinical or pharmaceutical science emphasis
• RAC (Regulatory Affairs Certification) from RAPS — US, EU, or both
• Master's degree in regulatory affairs accepted with extensive relevant experience

Experience:

• 12–18 years in regulatory affairs, with at least one successful NDA, BLA, or equivalent marketing authorization submission
• Direct FDA Type B and Type C meeting management
• Experience with INDs from Phase I through Phase III, including safety reporting
• Post-approval experience: supplements, annual reports, labeling updates
• For global roles: EMA CHMP scientific advice, centralized procedure, or national procedure experience

Regulatory science expertise:

• eCTD format and FDA electronic submission requirements (M1, M2–M5 modules)
• PDUFA commitments and FDA review timelines for standard and priority review
• Accelerated approval, breakthrough therapy, fast track, and RMAT designation criteria and processes
• REMS design and post-market safety obligation management
• Orphan drug, pediatric exclusivity, and patent/exclusivity considerations
• CMC regulatory requirements: drug substance and drug product changes, comparability protocols

Leadership skills:

• Regulatory team management: supervising regulatory managers and associates on concurrent programs
• Cross-functional influence: advising clinical, manufacturing, and commercial teams on regulatory constraints without creating operational paralysis
• Risk communication: framing regulatory risk in terms that enable business decisions, not just compliance descriptions

Directors of Regulatory Affairs are consistently in high demand across the life sciences industry. The FDA approval pipeline shows no sign of shrinking — over 50 novel drugs, biologics, and devices are approved each year — and each approval represents years of IND management, Type B meetings, and NDA or BLA submissions that required experienced regulatory leadership.

The complexity of the regulatory landscape has grown substantially. FDA's requirements for clinical trial diversity, real-world evidence integration, post-market surveillance, and AI/ML-based products have expanded the regulatory director's scope. EMA's post-Brexit evolution, Japan's PMDA harmonization agenda, and emerging requirements from China's NMPA have added global dimensions to programs that previously needed only U.S. and EU expertise.

Former FDA staff — particularly reviewers and division directors from CDER, CBER, and CDRH — are among the most sought-after regulatory directors in industry. Their understanding of agency review culture, how decisions are actually made inside divisions, and which arguments are persuasive to specific review teams is difficult to develop from the outside. Companies entering pivotal development or approaching first submissions pay significant premiums for this background.

Biotech's continued growth has created a steady supply of new regulatory director positions at pre-commercial companies building their regulatory functions for the first time. These roles offer equity and the chance to define the regulatory strategy from the ground up — which is attractive to experienced Directors who want more ownership than a large pharma function provides.

At the VP of Regulatory Affairs level, total compensation including bonus and equity at a mid-to-large pharma company regularly exceeds $300K–$400K. For regulatory professionals who accumulate multiple successful submissions and broad therapeutic area expertise, that level is achievable within 5–8 years of the Director role.

Dear Hiring Manager,

I'm applying for the Director of Regulatory Affairs position at [Company]. I hold a PhD in Pharmacology from [University] and the RAC (US) credential, and I've spent the past eight years in pharmaceutical regulatory affairs — most recently as Senior Regulatory Manager at [Company], where I've led the IND program for two clinical-stage compounds and contributed to one successful NDA submission.

On our NDA program, I managed the electronic Common Technical Document (eCTD) preparation from database lock through acceptance, coordinating the clinical summary sections, the safety update, and the CMC modules with our manufacturing partner. I also led the pre-NDA meeting with FDA's [Division], prepared the briefing document, and developed the proprietary labeling strategy. The application received a standard review designation and approval in the first review cycle with one labeling negotiation round.

I have direct experience with breakthrough therapy designation strategy — I prepared the designation request for our second compound, which was granted based on Phase Ib data. Managing the enhanced FDA engagement that comes with breakthrough designation — the more frequent and substantive review meetings, the rolling review option — has been the most valuable learning experience of my career.

I'm interested in [Company] specifically because your [program description] is at a regulatory inflection point where the Phase III design conversation with FDA will define the approval path. That is exactly the kind of high-stakes regulatory challenge I find most engaging.

Thank you for your consideration.

[Your Name]